WaveMan
WaveMan · Company
NUVL · Nuvalent, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

NUVL Nuvalent (NUVL) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001861560
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
193
13F, latest reported quarter
Conversions, 180 days
17
Codes C/M, not in net · $3.7M priced

What the filings say about NUVL

Insiders, 180 days
-$21.1M net sold
5 sellers · 0% of sales under a 10b5-1 plan

Nuvalent insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Nuvalent, Inc. insiders sold a net $21.1M of stock across 590 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
Pelish Henry E.
Chief Scientific Officer
SELL
2026-07-10 SECtraded 2026-07-09
2,111
$261.4K
n/a
Context
  • 43 earlier Form 4 trades (code P or S) here by this insider (43 sales), the last on Apr 9, 2026.
  • The trade is 3.3% of the 63,493 shares held after it.
  • 3 other insiders sold within 30 days.
  • 193 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Scientific Officer Pelish Henry E. sold about $261.4K of NUVL on Jul 9, 2026; 3 other insiders sold within 30 days and 193 funds added in the latest 13F quarter.
Porter James Richard
President and CEO
SELL
2026-07-08 SECtraded 2026-07-06
30,000
$3.7M
n/a
Context
  • 66 earlier Form 4 trades (code P or S) here by this insider (66 sales), the last on Jun 8, 2026.
  • The trade is 9.2% of the 324,879 shares held after it.
  • 3 other insiders sold within 30 days.
  • 193 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Porter James Richard sold about $3.7M of NUVL on Jul 6, 2026; 3 other insiders sold within 30 days and 193 funds added in the latest 13F quarter.
Balcom Alexandra
Chief Financial Officer
SELL
2026-07-06 SECtraded 2026-07-01
11,430
$1.4M
n/a
Context
  • 80 earlier Form 4 trades (code P or S) here by this insider (80 sales), the last on Jun 1, 2026.
  • The trade is 13.4% of the 85,533 shares held after it.
  • 3 other insiders sold within 30 days.
  • 193 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Balcom Alexandra sold about $1.4M of NUVL on Jul 1, 2026; 3 other insiders sold within 30 days and 193 funds added in the latest 13F quarter.
Noci Darlene
Chief Development Officer
SELL
2026-07-06 SECtraded 2026-07-01
23,000
$2.8M
n/a
Context
  • 134 earlier Form 4 trades (code P or S) here by this insider (134 sales), the last on Jun 29, 2026.
  • The trade is 39.6% of the 58,117 shares held after it.
  • 3 other insiders sold within 30 days.
  • 193 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Development Officer Noci Darlene sold about $2.8M of NUVL on Jul 1, 2026; 3 other insiders sold within 30 days and 193 funds added in the latest 13F quarter.
Noci Darlene
Chief Development Officer
SELL
2026-07-01 SECtraded 2026-06-29
5,500
$679.3K
n/a
Context
  • 133 earlier Form 4 trades (code P or S) here by this insider (133 sales), the last on Jun 9, 2026.
  • The trade is 9.5% of the 58,117 shares held after it.
  • 3 other insiders sold within 30 days.
  • 193 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Development Officer Noci Darlene sold about $679.3K of NUVL on Jun 29, 2026; 3 other insiders sold within 30 days and 193 funds added in the latest 13F quarter.
590 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 585 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$21.1M over 180 days
below 88% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
193 funds bought in last quarter
more than 89% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
no short interest reported
What changed in the last 30 days
Oct 27Insider selling stopped: no sales in 90 days after 34 in the prior 90
Why it matters
The absence is the signal: 34 sales in one 90-day window and none in the next is a change of behaviour, not a filing.

Watch NUVL

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

Who owns NUVL: institutional holders (13F)

13F holdings, latest reported quarter
DEERFIELD MANAGEMENT COMPANY, L.P.
17,248,450 sh
$2.1B
Paradigm Biocapital Advisors LP
5,924,433 sh
$731.7M
BlackRock, Inc.
5,585,619 sh
$689.8M
HBK INVESTMENTS L P
3,483,100 sh
$430.2M
FIL Ltd
2,946,506 sh
$363.9M

Congress trades in NUVL

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

NUVL planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
Henry E. Pelish
Filed 2026-07-09
$261.4K
Alexandra Balcom
Filed 2026-07-01
$2.8M

NUVL mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
First Trust Merger Arbitrage Fund
$88.6M position · as of 2026-06-30
5.4%
Nexpoint Merger Arbitrage Fund
$73.9M position · as of 2026-06-30
5.0%
Tema Oncology ETF
$5.9M position · as of 2026-05-31
3.4%
Alger Small Cap Growth Portfolio
$3.4M position · as of 2026-06-30
2.0%
Comstock Capital Value Fund
$185.2K position · as of 2026-06-30
1.7%
AlphaCentric Life Sciences and Healthcare Fund
$686.4K position · as of 2026-06-30
1.5%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
6 registered trials, 4 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
1
Phase 1
1 active
1
Phase 3
1 active
2
Not applicable
0 active
2
Multi-phase
2 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$11.4M
$18.3M
$4.2M
+428%
+25%
2024
$17.3M
$21.1M
$5.5M
+311%
-7%
2023
$9.4M
$50.5M
$3.6M
+286%
-6%
2022
$5.2M
$13.9M
$2.0M
+56%
-10%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $21.1M sold by insiders over 180 days, 193 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXTWSTKYMR

NUVL financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
n/a
capex not filed for the four quarters
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-41.2%
TTM net income over average of 2025-03-31 and 2026-03-31
Return on assets
-36.9%
TTM net income over average of 2025-03-31 and 2026-03-31
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-38.5%
operating income (EBIT proxy) over average of 2025-03-31 and 2026-03-31 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no share count filed
FCF yield
n/a
no share count filed
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-07-21. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Operating income-$414.3M-$280.4M-$149.5M-$86.1M
Net income-$425.4M-$260.8M-$126.2M-$81.9M
EPS (diluted)-5.85-3.93-2.17-1.65
Operating cash flow-$275.2M-$185.1M-$99.7M-$65.0M
Cash$261.7M$145.7M$335.4M$241.8M
SEC XBRL, fiscal years, as known on 2026-10-27

NUVL Stock Sonar score 3/7 axes

Find similar shapesCompare

NUVL ranks highest on institutional and government (89th percentile) and profitability (58th), and lowest on insider conviction (5th), among Pharma & Biotech peers.

Profitability
58
Inputs
  • Return on equity-41.2% · 59 pct, sector of 545
  • Return on assets-36.9% · 55 pct, sector of 691
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-38.5% · 60 pct, sector of 576
Insider conviction
5
Inputs
  • Net Form 4 buying (codes P and S), 180d-$21.1M · 10 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
89
Inputs
  • Funds adding, latest quarter193 · 89 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
4 not measured: Financial health, Growth, Risk and compliance, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • Risk and compliance needs 1 of 4 inputs, 0 present: needs two 10-Ks with a Risk Factors section (not 20-F filers or stubs); no short interest or no free float on file; revenue under $50M or not filed, so a count cannot be scaled to size
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

3 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

NUVL filings, in plain words

Are Nuvalent insiders buying or selling NUVL?

In the 180 days to 2026-10-27, Nuvalent insiders were net sellers, a net $21.1M across purchases and sales reported on Form 4, by 5 sellers.

Read the full summary

In the 180 days to 2026-10-27, Nuvalent insiders were net sellers of NUVL, a net $21.1M across purchases and sales reported on Form 4 by 5 sellers. None of the 36 insider sales was flagged as made under a Rule 10b5-1 plan. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies